Short-term Outcome in Ischemic Stroke Patients after Thrombolytic Therapy
Agban, E., AbdElghaffar, A., Abdel Gawad, A., s mohamed, W. (2022). Short-term Outcome in Ischemic Stroke Patients after Thrombolytic Therapy. EKB Journal Management System, 28(6.1), 280-285. doi: 10.21608/zumj.2020.25949.1773
Emad Latif Agban; Adel AbdElghaffar; Ahmed Abdel Gawad; wafaa s mohamed. "Short-term Outcome in Ischemic Stroke Patients after Thrombolytic Therapy". EKB Journal Management System, 28, 6.1, 2022, 280-285. doi: 10.21608/zumj.2020.25949.1773
Agban, E., AbdElghaffar, A., Abdel Gawad, A., s mohamed, W. (2022). 'Short-term Outcome in Ischemic Stroke Patients after Thrombolytic Therapy', EKB Journal Management System, 28(6.1), pp. 280-285. doi: 10.21608/zumj.2020.25949.1773
Agban, E., AbdElghaffar, A., Abdel Gawad, A., s mohamed, W. Short-term Outcome in Ischemic Stroke Patients after Thrombolytic Therapy. EKB Journal Management System, 2022; 28(6.1): 280-285. doi: 10.21608/zumj.2020.25949.1773

Short-term Outcome in Ischemic Stroke Patients after Thrombolytic Therapy

Zagazig University Medical Journal
Article 39, Volume 28, Issue 6.1, November 2022, Page 280-285  XML PDF (225.09 K)
Document Type: Original Article
DOI: 10.21608/zumj.2020.25949.1773
View on SCiNiTO View on SCiNiTO
Authors
Emad Latif Agban1; Adel AbdElghaffar1; Ahmed Abdel Gawad email 2; wafaa s mohamed3
1Neurology department,faculty of medicine,Zagazig university,Egypt
2Nasser Institute for Research and Treatment, Cairo,Egypt
3Neurology department faculty of medicine zagazig university
Abstract
Objective: Recombinant tissue plasminogen activator (rt-PA, alteplase), as the primary thrombolytic agent, has been proved effective and beneficial in patients with acute ischemic stroke (AIS). This study aimed to predict the three months outcome of AIS patients who received thrombolytic therapy regarding mortality, symptomatic intracerebral hemorrhage (sICH) and functional outcome in comparison to non thrombolyzed patients.
Patients and methods: This study included 80 patients with AIS who attended Zagazig University Hospital (ZUH) during the period from Feb 2016 to Feb 2018. Patients were divided into two groups; Group I included 40 AIS patients who received rt-PA within 4.5 hours from symptom onset. Group II included 40 AIS patients (as a control group) who received regular treatment, rather than rt-PA within the first 24 hours from symptom onset, they were selected to match group I as regard baseline data. Stroke severity was assessed by National Institute of Health Stroke Scale (NIHSS). Modified Rankin Scale (mRS) was used to measure 3 months functional outcome.
Result: After 3 months follow–up, death rate was slightly higher among group I (7.5%) compared to group II (5%). 7.5 % of group I patients had sICH compared to 5% of group II patients, this difference was not statistically significant. More patients in group I had favorable outcome (mRS=0-2) than group II (65% vs. 60%, OR1.38, 95% CI 0.50-3.6, P 0.51).
Conclusion: After 3 months follow up, rt-PA was more frequently associated with favorable outcome; however, it increased the risk of sICH and death compared to controls.
Keywords
Recombinant tissue plasminogen activator; AIS patients; alteplase
Statistics
Article View: 248
PDF Download: 84